Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines

Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-designed pivotal trials, allow for this robust cha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Vaccine
Main Authors: Vannice, Kirsten S., Wilder-Smith, Annelies, Barrett, Alan D.T., Carrijo, Kalinka, Cavaleri, Marco, de Silva, Aravinda, Durbin, Anna P., Endy, Tim, Harris, Eva, Innis, Bruce L., Katzelnick, Leah C., Smith, Peter G., Sun, Wellington, Thomas, Stephen J., Hombach, Joachim
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010224/
https://ncbi.nlm.nih.gov/pubmed/29525283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2018.02.062
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados